Type 2 diabetes and obesity are commonly accompanied by metabolic dysfunction–associated steatotic liver disease (MASLD), increasing the risk of developing metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis. The early stages of MASLD are characterized by dysfunctional lipid metabolism, including remodeling of the hepatic lipidome. In this context, reductions in hepatic phosphatidylserine (PS) have been associated with […]
Read MoreCategory: Diabetes
Type 2 Diabetes Genetic Risk and Type 1 Diabetes Heterogeneity and Progression
Insulin secretion varies widely in preclinical type 1 diabetes. To understand the pathogenesis of this metabolic heterogeneity, we asked whether genetic predisposition to type 2 diabetes, quantified by a type 2 diabetes genetic risk score (T2D-GRS), modulates β-cell function and disease progression in individuals at risk of type 1 diabetes. We analyzed 4,324 islet autoantibody–positive […]
Read MoreUrinary Dickkopf-3 Reveals Tubular Fibrosis and Hidden Progression in Diabetic Kidney Disease
The study by Keller et al. (1) demonstrated that urinary Dickkopf-3 (uDKK3) independently predicted kidney function decline and mortality among individuals with type 2 diabetes managed in primary care. However, a reassessment of their data reveals two clinically important yet underexplored patterns and several potential methodological limitations that may influence both interpretation and applicability. Source link
Read MoreIssues and Events
Issues and Events Source link
Read MoreDiabetes Spotlight: Jay M. Sosenko, MD—Diabetic Neuropathy and Prevention Strategies for Type 1 Diabetes
For a career in diabetes, Jay Sosenko was in the right place at the right time. He had just started a fellowship in adolescent medicine at the Children’s Hospital Medical Center in Boston when he heard about a new breakthrough making waves in medicine. The attending physician in the adolescent diabetes clinic, Dr. Kenneth Gabbay, […]
Read More
Automated Insulin Delvery Part 2
In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss with the benefits of Automated Insulin Delivery for people with Type 2 Diabetes. This special episode is supported by an independent educational grant from Insulet. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, […]
Read More
Diabetes Core Update Jan 2026
This issue will review: 1. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke 2. SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 3. Continuous SGLT-2, GLIP-1RA and Frailty Progression in Older Adults with Type 2 Diabetes 4. Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of […]
Read More
Special Edition- Weight Bias and Stigma – Part 1
In this special series on Weight Bias and Stigma our host, Dr. Neil Skolnik will discuss weight bias and stigma and its importance because weight bias and stigma have an important impact the experience of living with obesity, leads to measurable adverse outcomes, and when it is present in health care interactions it affects all […]
Read MoreParadoxical Maturity-Onset Diabetes of the Young Arising From Loss-of-Function Mutations in ATP-Sensitive Potassium Channels
Pancreatic β-cell ATP-sensitive K+ (KATP) channel closure underlies electrical excitability and insulin release, but loss or inhibition of KATP channels can lead to paradoxical crossover from hyperinsulinism plus hypoglycemia, to glucose intolerance or diabetes. We report genotype-phenotype information from a set of patients clinically diagnosed with maturity-onset diabetes of the young (MODY) and carrying coding […]
Read MoreDickkopf-3 (DKK3) and the Progression of Diabetic Kidney Disease in Primary Health Care
Accurate prediction of diabetic kidney disease progression is challenging, but mandatory. Urinary Dickkopf-3 (uDKK3), a tubular, epithelial-derived glycoprotein and marker of tubular injury, is a promising biomarker for kidney function decline. We explored the clinical utility of uDKK3 to predict kidney function decline and adverse cardiovascular events in patients with type 2 diabetes mellitus (T2DM) […]
Read More